Digital tool to help young adults quit vaping with ACT on Vaping app
Official title: ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation
Run by Fred Hutchinson Cancer Center · NCT06909500 · Data updated 2026-11-12
A smartphone app using Acceptance and Commitment Therapy is tested to see if it helps 18-30 year-olds quit vaping, compared to a version with enhanced text support.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 30 Years |
| Sex | All |
| Enrollment | 1178 (estimated) |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Status | Recruiting |
| Started | May 20, 2026 |
| Main results expected | November 15, 2027 |
| Study ends | November 15, 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT06909500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 18-30 years old, current weekly e-cigarette users for at least 30 days, and have a compatible smartphone and data access.
✕Probably not a fit
Individuals not using smartphones or not willing to engage with a digital intervention may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests two versions of an ACT-based vaping cessation app among young adults who currently vape. Participants are randomized to Version A with text-messaging support plus incentive check-ins or Version B with incentivized check-ins only, both using the same app. Follow-up occurs at 3, 5.5, and 6 months after the intervention, with assessments of vaping status and engagement. The trial is led by Fred Hutchinson Cancer Center with NIDA as a collaborator and is conducted in Seattle, WA.
Why it matters
Potential benefit: If successful, the app could provide an accessible, digital option to support quitting vaping among young adults.
How similar studies have gone: Prior digital interventions for vaping cessation show promise, with behavioral apps and text support improving quit rates in young adults.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-30 * Current weekly user of e-cigarette product(s) for the last 30 days * Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent) * Experience downloading and using one or more apps on their smartphone * Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app * Has access to text messaging * Has an email address * United States (US) resident, with a US mailing address * Willing to complete all study procedures * Comfortable reading and writing in English Exclusion Criteria: * Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial participation) * Member of the same household as another research participant * Currently in prison * Google voice number as sole phone number, due to its association with fraudulent study entry attempts * Is ineligible per fraud prevention protocol * Employees/family of investigator or study center
Where it's running
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Jaimee Heffner, PhD — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Jaimee Heffner, PhD
- Email: jheffner@fredhutch.org
- Phone: 206-667-7314
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How people puff IQOS Iluma i vs IQOS 2.4 and how flavors feel
This study tests how exclusive IQOS users puff the newer Iluma i versus the older 2.4, and whether preferred flavor affects puffing and sensory experience.
-
Do a single nicotine pouch affect cigarette craving and brain response to smoking cues
This study tests whether a single 6 mg oral nicotine pouch can reduce craving and alter prefrontal brain responses to smoking cues in adults who smoke cigarettes.
-
Comparative evaluation of nicotine analogs for nicotine EC users
This early-stage trial tests whether two nicotine-like compounds (6-MN and nicotinamide) differ from nicotine in how they feel, how much people use them, and how they affect the body in adult e-cigarette users.
-
TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping
This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.
-
Social media support groups to help teens and young adults quit vaping
This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.
-
How nicotine pouches affect users and public health
This study tests different nicotine pouch types and concentrations to see how they feel to users and whether people switch from cigarettes to pouches.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.